Facebook Twitter LinkedIn Google Plus RSS

J&J unit teaming up to create HIV tablet

By

A unit of New Brunswick-based Johnson & Johnson will work with a unit of GlaxoSmithKline on developing a single-tablet HIV regimen.

ViiV Healthcare, owned by Glaxo, announced Thursday that it will work with Janssen R&D Ireland, owned by J&J, to develop and commercialize a pill that combines human immunodeficiency virus medicines from both companies.

Studies are expected to begin by the first quarter of 2015, according to a news release.

“New options that advance current therapies are increasingly important as patients and clinicians consider HIV care over the long term,” Dr John Pottage, chief medical officer, ViiV Healthcare, said in the release. “Through this collaboration with Janssen we aim to develop a new combination therapy that meets the needs of patients.”

ALSO ON NJBIZ:

Open up and say 'transition': More dentists buying peers' practices

When should sales tax be collected online? Garden State residents can't make up their minds

Advance, F. Greek Development break ground on warehouse in Woodbridge

Eric Strauss

Eric Strauss

Eric Strauss is the digital content editor for NJBIZ. He has been a reporter and editor for newspapers in New Jersey and Pennsylvania, as well as for a number of websites. You can contact him at erics@njbiz.com or @acerimrat on Twitter.

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!